Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer
- 1 September 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (17) , 4491-4502
Abstract
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohydrolase (PARG) is a strong candidate target due to its dependence on the pro-oncogenic mRNA stability factor HuR (ELAVL1). Here, we evaluated PARG as a target in PDAC models using both genetic silencing of PARG and established small-molecule PARG inhibitors (PARGi), PDDX-01/04. Homologous repair–deficient cells compared with homologous repair–proficient cells were more sensitive to PARGi in vitro. In vivo, silencing of PARG significantly decreased tumor growth. PARGi synergized with DNA-damaging agents (i.e., oxaliplatin and 5-fluorouracil), but not with PARPi therapy. Mechanistically, combined PARGi and oxaliplatin treatment led to persistence of detrimental PARylation, increased expression of cleaved caspase-3, and increased γH2AX foci. In summary, these data validate PARG as a relevant target in PDAC and establish current therapies that synergize with PARGi. Significance: PARG is a potential target in pancreatic cancer as a single-agent anticancer therapy or in combination with current standard of care.Keywords
All Related Versions
Funding Information
- NIH-NCI (R01 CA212600)
- NIH-NCI (R37CA227865)
- NCI of the NIH (P30CA056036)
- Cancer Research UK (C480/A11411, C5759/A17098)
This publication has 62 references indexed in Scilit:
- PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathwaysCell Death & Disease, 2013
- Clonogenic Assay: Adherent CellsJournal of Visualized Experiments, 2011
- Biomarkers of PARP inhibitor sensitivityBreast Cancer Research and Treatment, 2011
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- A Syngeneic Variance Library for Functional Annotation of Human Variation: Application toBRCA2Cancer Research, 2008
- Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic OptionsGastroenterology, 2006
- Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD+ into a nuclear signalGenes & Development, 2005
- The Road to Survival Goes through PARGCell Cycle, 2005
- Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RASG12V oncogeneGastroenterology, 2004